Germany Rejects New ADHD Drug

von freakoutcrazy

Finding that Shire’s study of its successor to Adderall XR, Vyvanse, (lisdexamfetamine; known in Germany as Elvanse) was too short and did not look at the drug as part of a comprehensive treatment program, Germany’s Institute for Quality and Efficiency in Health Care said that the study “was neither sensible nor did it comply with the approval…  An added benefit of lisdexamfetamine is therefore not proven.”